JPWO2020020789A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020020789A5 JPWO2020020789A5 JP2021503578A JP2021503578A JPWO2020020789A5 JP WO2020020789 A5 JPWO2020020789 A5 JP WO2020020789A5 JP 2021503578 A JP2021503578 A JP 2021503578A JP 2021503578 A JP2021503578 A JP 2021503578A JP WO2020020789 A5 JPWO2020020789 A5 JP WO2020020789A5
- Authority
- JP
- Japan
- Prior art keywords
- disorders
- compound
- formula
- release system
- core
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 208000035475 disorder Diseases 0.000 claims description 20
- 230000003204 osmotic effect Effects 0.000 claims description 16
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 15
- 201000011190 diabetic macular edema Diseases 0.000 claims description 15
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 10
- 208000020832 chronic kidney disease Diseases 0.000 claims description 10
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 10
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 208000020084 Bone disease Diseases 0.000 claims description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 206010002383 Angina Pectoris Diseases 0.000 claims description 5
- 208000031229 Cardiomyopathies Diseases 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 201000006306 Cor pulmonale Diseases 0.000 claims description 5
- 206010012289 Dementia Diseases 0.000 claims description 5
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 5
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 5
- 206010019280 Heart failures Diseases 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 5
- 208000019693 Lung disease Diseases 0.000 claims description 5
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 5
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims description 5
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 5
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 5
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 5
- 201000007917 background diabetic retinopathy Diseases 0.000 claims description 5
- 210000003169 central nervous system Anatomy 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 230000003176 fibrotic effect Effects 0.000 claims description 5
- 208000019622 heart disease Diseases 0.000 claims description 5
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 claims description 5
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 208000028867 ischemia Diseases 0.000 claims description 5
- 210000003734 kidney Anatomy 0.000 claims description 5
- 208000030159 metabolic disease Diseases 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 201000006938 muscular dystrophy Diseases 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 230000002685 pulmonary effect Effects 0.000 claims description 5
- 230000009424 thromboembolic effect Effects 0.000 claims description 5
- 208000019553 vascular disease Diseases 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 239000013078 crystal Substances 0.000 claims description 3
- 208000029578 Muscle disease Diseases 0.000 claims description 2
- 208000021642 Muscular disease Diseases 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 108091006335 Prostaglandin I receptors Proteins 0.000 claims description 2
- 238000002441 X-ray diffraction Methods 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 229940125708 antidiabetic agent Drugs 0.000 claims description 2
- 239000002220 antihypertensive agent Substances 0.000 claims description 2
- 229940030600 antihypertensive agent Drugs 0.000 claims description 2
- 229960004676 antithrombotic agent Drugs 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 230000006806 disease prevention Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000002329 infrared spectrum Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000002840 nitric oxide donor Substances 0.000 claims description 2
- 239000003880 polar aprotic solvent Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 239000000018 receptor agonist Substances 0.000 claims description 2
- 229940044601 receptor agonist Drugs 0.000 claims description 2
- -1 sodium alkoxide Chemical class 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000003119 guanylate cyclase activator Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18185127 | 2018-07-24 | ||
| US16/043,567 US10905667B2 (en) | 2018-07-24 | 2018-07-24 | Orally administrable modified-release pharmaceutical dosage form |
| US16/043,567 | 2018-07-24 | ||
| EP18185127.0 | 2018-07-24 | ||
| PCT/EP2019/069561 WO2020020789A1 (de) | 2018-07-24 | 2019-07-19 | Oral applizierbare pharmazeutische darreichungsform mit modifizierter freisetzung |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021532113A JP2021532113A (ja) | 2021-11-25 |
| JP2021532113A5 JP2021532113A5 (https=) | 2022-07-26 |
| JPWO2020020789A5 true JPWO2020020789A5 (https=) | 2022-07-26 |
Family
ID=67314781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021503578A Pending JP2021532113A (ja) | 2018-07-24 | 2019-07-19 | 経口投与可能であり、放出を修飾した薬学的投薬形態 |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP3826627B1 (https=) |
| JP (1) | JP2021532113A (https=) |
| KR (1) | KR20210035235A (https=) |
| CN (1) | CN112469402B (https=) |
| AU (1) | AU2019311234A1 (https=) |
| BR (1) | BR112020026644A2 (https=) |
| CA (1) | CA3107169A1 (https=) |
| CL (1) | CL2021000160A1 (https=) |
| CO (1) | CO2021000450A2 (https=) |
| CR (1) | CR20210043A (https=) |
| DO (1) | DOP2021000015A (https=) |
| EC (1) | ECSP21003707A (https=) |
| IL (1) | IL280083A (https=) |
| JO (1) | JOP20210019A1 (https=) |
| MA (1) | MA53368A (https=) |
| MX (1) | MX2021000904A (https=) |
| PE (1) | PE20210415A1 (https=) |
| PH (1) | PH12021550170A1 (https=) |
| SG (1) | SG11202100369WA (https=) |
| TW (1) | TW202019402A (https=) |
| UY (1) | UY38308A (https=) |
| WO (1) | WO2020020789A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020245342A1 (en) | 2019-06-07 | 2020-12-10 | Bayer Aktiengesellschaft | The use of sgc activators for the treatment of ophthalmologic diseases |
| CN112557533A (zh) * | 2020-11-29 | 2021-03-26 | 北京康立生医药技术开发有限公司 | 一种恩格列净的分析方法 |
| US20240317696A1 (en) * | 2021-05-14 | 2024-09-26 | Medshine Discovery Inc. | Alkyl carboxylic acid compounds and application thereof |
| EP4536205A1 (en) | 2022-06-09 | 2025-04-16 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
| CN117982443B (zh) * | 2022-10-31 | 2026-03-06 | 优辉药业(北京)有限公司 | 一种达格列净二甲双胍缓释片剂 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US4063064A (en) | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
| US4111202A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| NZ206600A (en) | 1983-05-11 | 1987-01-23 | Alza Corp | Osmotic drug delivery device |
| US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
| ES2039287T3 (es) | 1987-01-14 | 1993-09-16 | Ciba-Geigy Ag | Procedimiento para la obtencion de un sistema terapeutico peroral para productos activos dificilmente solubles. |
| DE19747261A1 (de) | 1997-10-25 | 1999-04-29 | Bayer Ag | Osmotisches Arzneimittelfreisetzungssystem |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| ATE433318T1 (de) * | 1999-02-10 | 2009-06-15 | Pfizer Prod Inc | Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| US20030161882A1 (en) | 2002-02-01 | 2003-08-28 | Waterman Kenneth C. | Osmotic delivery system |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| DE102004062475A1 (de) | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
| DE102008059206A1 (de) | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| PE20130779A1 (es) | 2010-07-09 | 2013-06-21 | Bayer Ip Gmbh | Pirimidinas y triazinas condensadas y su uso |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| DE102011007272A1 (de) * | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
| UY34856A (es) * | 2012-07-03 | 2013-12-31 | Bayer Pharma AG | Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida |
| WO2019105881A1 (de) | 2017-12-01 | 2019-06-06 | Bayer Pharma Aktiengesellschaft | Verfahren zur herstellung von (3s)-3-(4-chlor-3-{[(2s,3r)-2-(4-chlorphenyl)-4,4,4-trifluor-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropansäure und dessen kristalline form für die verwendung als pharmazeutischer wirkstoff |
-
2019
- 2019-07-19 CA CA3107169A patent/CA3107169A1/en active Pending
- 2019-07-19 JP JP2021503578A patent/JP2021532113A/ja active Pending
- 2019-07-19 EP EP19740580.6A patent/EP3826627B1/de active Active
- 2019-07-19 JO JOP/2021/0019A patent/JOP20210019A1/ar unknown
- 2019-07-19 AU AU2019311234A patent/AU2019311234A1/en not_active Abandoned
- 2019-07-19 BR BR112020026644-2A patent/BR112020026644A2/pt not_active Application Discontinuation
- 2019-07-19 UY UY0001038308A patent/UY38308A/es not_active Application Discontinuation
- 2019-07-19 CR CR20210043A patent/CR20210043A/es unknown
- 2019-07-19 MX MX2021000904A patent/MX2021000904A/es unknown
- 2019-07-19 WO PCT/EP2019/069561 patent/WO2020020789A1/de not_active Ceased
- 2019-07-19 MA MA053368A patent/MA53368A/fr unknown
- 2019-07-19 CN CN201980049223.8A patent/CN112469402B/zh active Active
- 2019-07-19 PE PE2021000084A patent/PE20210415A1/es unknown
- 2019-07-19 KR KR1020217004994A patent/KR20210035235A/ko not_active Withdrawn
- 2019-07-19 TW TW108125542A patent/TW202019402A/zh unknown
- 2019-07-19 SG SG11202100369WA patent/SG11202100369WA/en unknown
-
2021
- 2021-01-11 IL IL280083A patent/IL280083A/en unknown
- 2021-01-18 EC ECSENADI20213707A patent/ECSP21003707A/es unknown
- 2021-01-19 CO CONC2021/0000450A patent/CO2021000450A2/es unknown
- 2021-01-20 DO DO2021000015A patent/DOP2021000015A/es unknown
- 2021-01-20 CL CL2021000160A patent/CL2021000160A1/es unknown
- 2021-01-22 PH PH12021550170A patent/PH12021550170A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021532113A5 (https=) | ||
| JP2022190161A (ja) | グルコキナーゼ活性化剤およびビグアナイド系血糖降下薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用 | |
| CN105561311B (zh) | 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和nsaid的药物组合物 | |
| JP2904588B2 (ja) | 抗片頭痛インドール誘導体塩類 | |
| CN112469402B (zh) | 可口服给药且缓释的药物剂型 | |
| JP5547865B2 (ja) | アプリンドルおよびその誘導体を含む持続放出型医薬組成物 | |
| EP2085076B1 (en) | Pharmaceutical composition in the form of coated microspheres for the modified release of a muscle relaxant and an nsaid | |
| JP2003518061A (ja) | シクロオキシゲナーゼ−２阻害剤の持続放出製剤 | |
| CN105012301A (zh) | 代谢型谷氨酸受体5(mglu5)拮抗剂的药物组合物 | |
| JPWO2020020789A5 (https=) | ||
| TWI834634B (zh) | 醫藥化合物、其鹽類、其製劑及其等之製備和使用之方法 | |
| JP2021531297A5 (https=) | ||
| WO2020020790A1 (de) | Oral applizierbare pharmazeutische darreichungsform mit modifizierter freisetzung | |
| KR102369607B1 (ko) | 암로디핀 및 로잘탄을 포함하는 고형 약제학적 조성물 | |
| EP2638898A1 (en) | Metformin and Pioglitazone Formulation with Different Release Profiles | |
| CN105431140A (zh) | 含有缓释二甲双胍和速释HMG-CoA还原酶抑制剂的复合制剂 | |
| JPWO2020020790A5 (https=) | ||
| CN110237072B (zh) | 药物组合物的制备方法 | |
| CN114224859A (zh) | 一种复方降压药物组合物及其制备方法 | |
| CA3210689A1 (en) | Fixed-dose pharmaceutical compositions | |
| HK40041248A (en) | Pharmaceutical dosage form which can be administered orally and has modified release | |
| US11065241B2 (en) | Pharmaceutical composition comprising quinoline derivative or salt thereof | |
| JPWO2023051490A5 (https=) | ||
| JP2002512262A (ja) | Ｒ−レイブプラゾール組成物及び方法 | |
| CN110237071B (zh) | 药物制剂及其应用 |